AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy

AXONIS Therapeutics, Inc., an emerging biotechnology company advancing breakthrough research to treat spinal cord injury and paralysis, today announced the close of the first tranche of a $4 million Seed Preferred financing. The financing was led by Kerry Murphy, an investor, philanthropist and AXONIS Board member. The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity. The importance of KCC2 treatment in recovery of stepping ability was first discovered by Dr